Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors

Stephanie E Combs; Monika Nagy; Lutz Edler; Renate Rausch; Marc Bischof; Thomas Welzel; Jürgen Debus; Daniela Schulz-Ertner

doi:10.1016/j.radonc.2008.03.005

Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors

Radiother Oncol. 2008 Aug;88(2):177-82. doi: 10.1016/j.radonc.2008.03.005. Epub 2008 Apr 18.

Authors

Stephanie E Combs¹, Monika Nagy, Lutz Edler, Renate Rausch, Marc Bischof, Thomas Welzel, Jürgen Debus, Daniela Schulz-Ertner

Affiliation

¹ University Hospital of Heidelberg, Department of Radiation Oncology, Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de

PMID: 18395280
DOI: 10.1016/j.radonc.2008.03.005

Abstract

Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated. No significant difference in overall survival or progression-free survival between both groups was calculated. RCHT seems not to result in an improved outcome. Further randomized studies are needed to support these results.

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating / therapeutic use*
Astrocytoma / drug therapy*
Astrocytoma / pathology
Astrocytoma / radiotherapy*
Astrocytoma / surgery
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Brain Neoplasms / radiotherapy*
Brain Neoplasms / surgery
Child
Combined Modality Therapy
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Disease Progression
Female
Humans
Male
Middle Aged
Proportional Hazards Models
Retrospective Studies
Survival Analysis
Temozolomide
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Dacarbazine
Temozolomide